Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
THERASOLVE One line pitch: TheraSolve develops MemoPatch, a groundbreaking therapy adherence technology that supports patients anywhere, anytime. It's simple, smart and small. Market Analysis: Patient noncompliance with their prescribed medication regimens is a highly prevalent problem with a significant impact on treatment outcome. Across disease states, 1/3 of patients are noncompliant with their medication regimens leading to a 26% differential in therapeutic benefit. Noncompliance impacts all stakeholders in healthcare: poor patient outcomes, clinician frustration, increased healthcare expenditures, lost sales and profitability for pharma. In 64% of cases, forgetfulness is the main reason for noncompliance. Innovative patient-centric solutions in PD, AD, HCV, HIV, MS, Epilepsy, Oncology and others have high business potential. Business Proposition: MemoPatch® technology consists of a new generation of self-adhesive and fully automated dermal patches which give patients a stimulus on the skin when it is time to take a next dose of medication. The patch has the potential to encompass various medication delivery forms and regimens including pills, inhalers, eye drops, patches, ointments, injections and other. The objective of the product is to help patients in the simplest, most discreet, user-friendly and, most of all, reliable way to successfully adhere to their medication regimens over a longer period of time, anywhere and anytime, regardless of the location or activity of the user. Competitive Advantage: MemoPatch is: Extremely simple and user-friendly, understandable for all - No battery to be charged - Pre-programmed - Fully automated - Optimal patient privacy - Reminds anywhere, anytime - Highly unique drug intake reminder signal perceptible on the skin - Even works for elderly, deaf and blind people - Cost-effective - Combinable with different drug types - Integration option with transdermal drug patches - Synergies of excellence with other healthcare technology platforms. Investment Attractiveness: TheraSolve successfully closed Seed (2011) and Series-A (2014) rounds and is currently preparing a Series B (2016). With the additional resources the company will bring its Standard MemoPatch technology to market, expand the product portfolio with transdermal as well as next generation MemoPatch solutions, and realize an exit. We welcome investment companies to learn more about our projects and the investment opportunity of excellence. IP Situation: Granted Patents in key pharmaceutical markets: Europe, United States, Japan, China, India. COMPANY PROFILE • Website: www.therasolve.com • Activity: eHealth • Contact: DE GEEST Wim [email protected] • Location: Agoralaan Building Abis 3590 Belgium • Founded in: 25/05/2009 • Employees: 7 • Management: van Dijck Bram CEO De Geest Wim CBDO De Geest Jan CTO Abraham Ivo CSO Heykants Els Program Manager Hermans Ruben Project Manager • Financial information (€): - Company stage: Preparing series B - Capital raised to date: 4.5 MEUR - Monthly burn rate: - Capital seeking and date: • Investors: Thuja Capital, LRM, AAAF, Founders • Referred by: Capricorn Investment Fund Dr. Frank Bulens